RxDoctor Payments Data

David McHenry, MD

Neurology · Jackson, MSNPI 1053494831

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 1,023 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 6.8% — the pattern of someone who eats at a lot of different presentations.

$18,366in general payments, 2019–2025

Across 1,023 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$1K
  • Novartis$1K
  • Pfizer$958
  • Acadia Pharmaceuticals Inc$933
  • Genentech USA, Inc.$786
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$1821%
  • Food & beverage$18,17699%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.75$1,241
AbbVie(2 entities)87$1,177
Novartis81$1,108
Pfizer64$958
Acadia Pharmaceuticals Inc63$933
Genentech USA, Inc.47$786
UCB, Inc.38$690
SK Life Science, Inc.31$682
Sanofi28$629
Argenx US, Inc.20$628
Medtronic(2 entities)34$602
Biogen31$580
Lilly USA, LLC25$569
AstraZeneca(2 entities)29$556
EMD Serono, Inc.25$416
Lundbeck LLC22$410
Otsuka America Pharmaceutical, Inc.16$375
Neurocrine Biosciences, Inc.21$372
Amgen(2 entities)21$365
ANI Pharmaceuticals, Inc.19$357
Sunovion Pharmaceuticals Inc.19$304
Eisai Inc.12$293
E.r. Squibb & Sons, L.L.C.14$266
Acorda Therapeutics, Inc12$245
Catalyst Pharmaceuticals, Inc.9$241
Jazz Pharmaceuticals Inc.12$226
Bristol Myers Squibb15$217
TG Therapeutics, Inc.2$203
Amylyx Pharmaceuticals, Inc.12$185
Avanir Pharmaceuticals, Inc.12$184
Livanova USA, Inc.8$155
Biohaven Pharmaceutical Holding Company Ltd.10$153
GE HealthCare6$145
Microtransponder, Inc.1$136
Neurelis, Inc.2$134
Boehringer Ingelheim1$125
Takeda Pharmaceuticals U.S.A., Inc.7$115
Supernus Pharmaceuticals, Inc.7$99
Sumitomo Pharma America, Inc.6$98
Kyowa Kirin, Inc.5$96
Biohaven Pharmaceuticals, Inc.6$93
MDD US Operations, LLC5$90
Johnson & Johnson(2 entities)5$75
Alnylam Pharmaceuticals Inc.4$69
Greenwich Biosciences, Inc.4$68
Corium, LLC3$67
Mallinckrodt Hospital Products Inc.3$66
Impel Pharmaceuticals Inc.3$62
Amneal Pharmaceuticals LLC4$57
Sanofi-aventis U.S. LLC3$57
Merz Pharmaceuticals, LLC2$54
Vanda Pharmaceuticals Inc.2$50
Grifols USA, LLC3$50
Novocure Inc.3$49
Adamas Pharmaceuticals, Inc.2$43
Axsome Therapeutics, Inc.2$43
Akcea Therapeutics, Inc.2$31
Chiesi USA, Inc.2$31
CSL Behring1$31
Mallinckrodt Enterprises LLC2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,366 in reported general payments places this provider in the 75th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$100,028
Medicare patients
545
Services billed
1,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate27$137,794
EliquisApixaban136$130,273
XareltoRivaroxaban43$46,403
AptiomEslicarbazepine Acetate12$30,661
Teriflunomide12$27,068
Aimovig AutoinjectorErenumab-Aooe20$14,627
NeuproRotigotine16$12,774
Levetiracetam239$8,073
Entacapone39$7,776
Carbamazepine ErCarbamazepine65$6,750
Carbidopa-LevodopaCarbidopa/Levodopa157$3,731
Memantine Hcl127$3,391
Primidone163$3,197
Topiramate123$3,039
Lacosamide22$2,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$933$137,79427 claims
PfizerEliquis$958$130,273136 claims
Johnson & JohnsonXarelto$75$46,40343 claims
Sunovion Pharmaceuticals Inc.Aptiom$304$30,66112 claims
UCB, Inc.Neupro$690$12,77416 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$57$1,24017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 neurology providers in Mississippi.

Other neurology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →